The FDA approved Xocova (ensitrelvir) on May 29, 2026 as the first oral antiviral cleared in the United States to prevent, rather than treat, symptomatic COVID-19 after exposure, per the agency's approval records. The indication covers adults and adolescents aged 12 and older following contact with someone infected with SARS-CoV-2.
Newspaper Daily publishes information, not medical advice. The outlet reports on regulatory actions and research findings and does not provide diagnosis or treatment guidance.
What the evidence showed
The approval rests on the phase 3 SCORPIO-PEP trial, in which a short course of ensitrelvir reduced the risk of developing symptomatic COVID-19 by roughly 67 percent after exposure, according to trial results cited in coverage of the decision. The program received Fast Track designation from the FDA, and the drug has been approved in Japan, its home market, since 2022 for treatment of established infection.
Ensitrelvir works differently from Paxlovid, the antiviral most often used for treatment: it targets a different step in the coronavirus replication cycle and is taken as a single daily tablet for several days after a known exposure.
Related stories: FDA Approves First Oral PCSK9 Inhibitor for High Cholesterol · FDA Approves Simtriyo, a First-in-Class Nonstimulant Pill for ADHD.
What this approval can and cannot show
The trial measured prevention of symptomatic illness after a recognized exposure, which is a narrow window. It does not establish that the drug prevents long COVID, severe disease, or onward transmission, and the results apply to people who know whom and when they were exposed, a situation that does not match every real-world contact. Timing also matters, because the course must start soon after the exposure to achieve the tested effect.
The labeled course is short, and the approval applies only to people who are not yet symptomatic; treatment of established infection remains a separate indication handled by other antivirals.
When to talk to a clinician
People with a confirmed exposure, particularly those at higher risk of severe COVID-19, can ask a clinician whether post-exposure antiviral use is appropriate. The approval does not change vaccination guidance; immunization remains the primary prevention tool per the CDC.